Final results of a phase II study of liposomal cisplatin				-vinorelbine combination as first-line treatment in HER2/neu negative metastatic breast cancer.

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.041 ◽

2010 ◽

Vol 10 (4) ◽

pp. 313-317 ◽

Cited By ~ 3

Author(s):

Juan de la Haba-Rodriguez ◽

Rosario González Mancha ◽

Gumersindo Pérez Manga ◽

Enrique Aranda Aguilar ◽

José Manuel Baena Cañada ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

Oncology ◽

10.1159/000097945 ◽

2006 ◽

Vol 70 (5) ◽

pp. 330-338 ◽

Cited By ~ 2

Author(s):

Ali I. Shamseddine ◽

Zaher K. Otrock ◽

Mohamad J. Khalifeh ◽

Hanan R. Yassine ◽

Maya Charafeddine ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Clinical Phase ◽

Sequential Combination ◽

Cisplatinum-Based Alternating Non-Cross-Resistant Chemotherapy as a First-Line Treatment in Metastatic Breast Cancer. A Phase II Study

Tumori Journal ◽

10.1177/030089169007600511 ◽

1990 ◽

Vol 76 (5) ◽

pp. 472-475 ◽

Cited By ~ 2

Author(s):

Krsto Kolarić ◽

Rudolf Tomek

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Cited By ~ 1

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2012.07.004 ◽

2012 ◽

Vol 12 (5) ◽

pp. 322-330 ◽

Cited By ~ 5

Author(s):

Rachel Borson ◽

Graydon Harker ◽

James Reeves ◽

Thaddeus Beck ◽

Steven Hager ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-005-9030-x ◽

2005 ◽

Vol 95 (1) ◽

pp. 45-53 ◽

Cited By ~ 26

Author(s):

M. Venturini ◽

C. Bighin ◽

S. Monfardini ◽

F. Cappuzzo ◽

N. Olmeo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1148 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1148-1148

Author(s):

R. Borson ◽

W. G. Harker ◽

J. E. Reeves ◽

J. Bromund ◽

L. Zhao ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Safety Analysis ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽

Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study

Breast Cancer Research and Treatment ◽

10.1023/a:1021158711030 ◽

2003 ◽

Vol 77 (1) ◽

pp. 1-8 ◽

Cited By ~ 6

Author(s):

E. Alba ◽

N. Ribelles ◽

A. Antón ◽

R. Pérez-Carrión ◽

J.M. López-Vega ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2011.03.019 ◽

2011 ◽

Vol 11 (4) ◽

pp. 211-220 ◽

Cited By ~ 23

Author(s):

Adam Brufsky ◽

Karen Hoelzer ◽

Thaddeus Beck ◽

Robert Whorf ◽

Mark Keaton ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORI-B01)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70883-8 ◽

2008 ◽

Vol 6 (7) ◽

pp. 217 ◽

Cited By ~ 1

Author(s):

S. Hurvitz ◽

H.J. Allen ◽

R.L. Moroose ◽

D. Chan ◽

C. Hagenstad ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽